A minority shareholder threatened to outspend the sale itself

The situation

Jacek called on a Thursday afternoon, and he opened with the sentence that usually means the rest of the call is going to take a while: 'I think we might have a real problem, and I don't know if it's a legal one or a money one.' He and Indah ran the management team of a specialty healthcare distribution company based in Brockville, a business Jacek, a pharmacist by training, had helped grow out of a single pharmacy relationship into a regional distributor before stepping fully into an executive role, and they were roughly two months into negotiating a sale of the business to a larger national distributor, a deal that would value the company somewhere between thirty-five and forty-five million dollars once working capital adjustments settled at closing.

The buyer's counsel had asked, as a condition of moving forward with the transaction, for the company to be continued into a different jurisdiction of incorporation before closing, a routine enough request in transactions where the buyer wants the target's governance framework to match its own corporate family and reporting structure. Jacek, as the operating executive, and Indah, the company's sales director, who had been with the company almost as long as Jacek had, brought the continuance to the board first, where it was approved unanimously in a meeting that lasted less than twenty minutes. A board cannot approve a continuance on its own, though: moving to a new jurisdiction of incorporation is a fundamental change under the corporate statute governing the company, requiring a special resolution passed by the shareholders themselves, at a properly noticed meeting, by at least a two-thirds majority. The board treated its own sign-off as the substantive decision and the shareholder vote that had to follow it as one line item among dozens on the pre-closing checklist, a formality to be scheduled rather than a step needing its own careful attention.

Zofia held a minority stake in the company, dating back to an early investment she had made years before the current sale process began, when the business was smaller and the risk to her capital had been considerably higher. She was not on the board and was not part of day-to-day operations, but her consent, or at minimum her acquiescence, mattered because minority shareholders retain real rights even when they hold no operational control over the company they invested in. When she learned of the continuance, she did not simply object informally. She retained her own counsel, formally challenged the process by which the board had approved it, and made clear, through her lawyer and directly to Jacek in an unpleasant phone call, that she had the personal resources to litigate the question for as long as it took, regardless of what defending it might cost the company.

That last part was the problem inside the problem. The company had a sale to protect on a fixed timeline and a modest legal budget to protect it with. Zofia had neither constraint working against her.

What the review found

Before responding to Zofia's objection with anything more than a holding letter acknowledging receipt, we did what her threat of a prolonged fight made necessary: a genuinely thorough review of how the continuance had actually been approved, rather than an assumption that the board's process had been clean simply because everyone involved had, in fact, acted in good faith throughout. Good faith and proper process are not the same thing in corporate governance, and an oppression-style claim from a minority shareholder often succeeds or fails on process details that nobody in the room was thinking about at the time the decision was made.

The review turned up two things, and they cut in opposite directions from each other. The first was a genuine gap in the record. The notice given to shareholders ahead of the meeting called to vote on the continuance had gone out later than the minimum period the corporate statute and the company's by-laws required for a special resolution, by a matter of days, and Zofia had a fair factual basis to say she had not received the notice she was legally entitled to. This was not anyone trying to exclude her deliberately; it was the kind of administrative slip that happens when a small management team is juggling a live sale process on top of ordinary corporate housekeeping. But a fair basis is a fair basis regardless of intent, and pretending otherwise would have handed Zofia a stronger claim than she actually had grounds to bring.

The second finding mattered considerably more to how the dispute would ultimately resolve. Zofia's underlying accusation, that the continuance was being used to strip or dilute her rights ahead of the sale in a way that specifically disadvantaged her as a minority holder relative to the founders, did not hold up against the actual documentary record once we assembled it. The continuance did not change the rights attached to her shares, did not alter her proportionate interest in the company, and did not affect what she stood to receive from the eventual sale relative to what Jacek and Indah stood to receive. Every shareholder, majority and minority alike, was treated identically by both the continuance resolution and the sale terms under discussion with the buyer. The notice defect was real and needed fixing. The substantive complaint underneath it was not, and the record showed that clearly.

One more fact shaped strategy without needing to be raised directly. Under the same statute, a shareholder who wants to dissent from a continuance and be paid fair value for her shares, rather than be carried into a new jurisdiction and a sale she opposed, has to follow the procedure exactly: written objection to the resolution delivered before or at the meeting, no vote in favour, and a written demand for payment within the prescribed period after the resolution passes. Miss a step and the right is lost; if the parties cannot agree on fair value, the court fixes it. Zofia never invoked that right, choosing to challenge the process instead — telling us she wanted leverage over the sale itself, not a fair-value exit.

That distinction, a real but narrow procedural flaw sitting on top of no real substantive harm at all, set the entire strategy for everything that followed.

What we did

1. Separated the notice defect from the substantive objection in every piece of correspondence. We conceded, in writing and early, that the shareholder notice had gone out late, because disputing a fact that was simply true would have undermined credibility on everything else. This let us frame Zofia's complaint accurately as a fixable procedural issue rather than let her characterize it as evidence of bad faith.
2. Cured the process defect directly rather than arguing it did not matter. We had the company call a fresh shareholders' meeting, give Zofia proper notice under the statute and the company's by-laws, and put the continuance back to a special resolution vote on a clean procedural footing. This removed her only genuine point of leverage within days, rather than leaving it as an open wound for her litigation counsel to keep pressing.
3. Requested Zofia's counsel articulate the specific harm the continuance caused her. An oppression-style claim needs to identify unfair prejudice to a particular shareholder, not just procedural irregularity, so we asked directly, in writing, what harm she said the continuance had caused relative to other shareholders. The answer, when it came, did not identify anything beyond the notice timing already cured.
4. Prepared a clear comparative summary of shareholder treatment for the record. We put together a document showing, share class by share class and shareholder by shareholder, that the continuance resolution and the proposed sale terms treated every holder identically regardless of the size of their stake, so that if the dispute did proceed further there would be an unambiguous, dated record showing no disparate treatment had ever existed.
5. Kept the sale timeline moving on a parallel track rather than freezing it. Rather than letting Zofia's objection stall the entire transaction while the dispute worked itself out, we kept the buyer's counsel informed and continued the closing process on schedule, on the basis that the underlying corporate step had already been properly cured and the substantive objection had no factual support standing behind it at all.
6. Declined to be drawn into a resource-based standoff. When Zofia's counsel suggested the dispute could run for months regardless of merit, we responded by narrowing the actual legal question in dispute at every turn rather than matching threat with threat, which kept the company's costs proportionate to a claim that, once the notice issue was cured, had little left to litigate.
7. Offered a straightforward resolution once the record was clear. With the process cured and the substantive complaint unsupported, we proposed a short written confirmation from Zofia acknowledging the corrected process, in exchange for closing out the dispute without further cost to either side. We kept the confirmation narrow, tied only to the continuance itself, so it could not be read later as a broader release of anything else Zofia might raise about the sale, which made it an easy document for her own counsel to recommend she sign.

The outcome

Zofia accepted the resolution. Once the notice defect was cured and her counsel could not point to any disparate treatment or quantifiable harm flowing from the continuance, the threatened extended fight had nothing substantive left to run on, and continuing to spend on it would have cost her real money for no gain. She signed the written confirmation acknowledging the corrected process, the continuance stood on its properly cured footing, and the sale closed within a few weeks of the original target date, with the buyer largely unaware of how close the deal had come to a genuine derailment.

This was a clear win, and it is worth being precise about what actually made it one, because the easy version of this story understates what was really at stake. It was not that Zofia's financial advantage turned out to be a bluff; she genuinely could have funded a longer fight than the company could comfortably afford to defend, and nothing about her resources or her resolve was ever in question. It was that the underlying legal question did not favour her once the one real procedural defect was identified and fixed, and a shareholder with deep pockets still needs a claim with actual substance to spend that money pursuing. Refusing to let her financial leverage substitute for merit in how we responded, while still promptly fixing the one thing that was genuinely wrong with the board's process, took away her only real point of pressure early enough in the dispute that the size of her war chest never actually came into play.

Jacek and Indah kept the sale on schedule and closed it on the terms originally negotiated, with no discount, delay penalty, or side settlement paid to Zofia. The company's legal costs on the objection stayed modest, a fraction of what a drawn-out fight would have cost over months, because the dispute was narrowed to its real substance within the first two weeks rather than sprawling across every grievance her counsel might otherwise have raised.

What you can learn from this